No form of ivermectin has been approved to treat or prevent COVID-19, the agency emphasized
MONDAY, Aug. 23, 2021 (HealthDay News) — Taking a drug meant for horses and cattle to prevent or treat COVID-19 is dangerous and could be fatal, the U.S. Food and Drug Administration warns.
The agency has received multiple reports of people who have been hospitalized after “self-medicating with ivermectin intended for horses,” the agency said in a consumer update. Ivermectin, which is not an antiviral drug, is generally used to treat or prevent parasites in animals. No form of ivermectin has been approved to treat or prevent COVID-19, the agency emphasized. It said it was compelled to issue a warning due to “a lot of misinformation” around the drug, according to the update.
The agency clarified that the FDA-approved ivermectin tablets that treat people with certain conditions caused by parasitic worms as well as topical formulations used for head lice and skin conditions like rosacea are different from the drug used on animals. Ivermectin tablets and topical formulations for humans have “very specific doses” that are significantly smaller than the doses meant for animals, the agency explained.
Also, “many inactive ingredients found in animal products aren’t evaluated for use in people. In some cases, we don’t know how those inactive ingredients will affect how ivermectin is absorbed in the human body,” the FDA warned. “These animal drugs are often highly concentrated because they are used for large animals like horses and cows, which can weigh a lot more than we do. Such high doses can be highly toxic in humans.”
The FDA said that ivermectin overdoses can cause nausea, vomiting, diarrhea, low blood pressure, allergic reactions, dizziness, problems with balance, seizures, coma, and even death.
Therapies Compared for Newly Diagnosed Multiple Sclerosis
Initial Rx Length Tied to Long-Term Use of Z-Drugs
Azacitidine + Venetoclax Tied to Improved Event-Free Survival in Adults With AML
Updated Recommendations Address Medications to Prevent Migraine in Adults
Paternal Exposure to Valproate Not Linked to Offspring Neurodevelopmental Disorders
December 2024 to 2025 Saw Significant Increase in Leucovorin Dispensing
Real-World ARIA Incidence With Lecanemab Aligns With Clinical Trial Findings
Many With Atypical Alzheimer Disease Do Not Qualify for Anti-Amyloid Therapy